USNANYSEMedicinal Chemicals & Botanical ProductsFiscal year ends January 3
USANA HEALTH SCIENCES INC
Financials through Q2 FY2026, quarter ended Jul 4, 2026Last filing: 10-Q on Aug 13, 2026
$14.89−0.65 (-4.18%)
Close on Oct 19, 2026
- Market cap
- $275.26M
- P/E (TTM)
- –
- Dividend yield
- –
USANA HEALTH SCIENCES INC revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Core Nutritional | $191.61M | $204.40M | – | – | $199.49M | $210.82M | – | – | – | – | – | – | 85.8% | -4.0% |
| Hiya | $28.26M | $32.15M | $30.11M | $30.85M | $33.93M | $37.09M | – | – | – | – | – | – | 12.7% | -16.7% |
| Rise | $3.41M | $13.67M | – | – | $2.43M | $1.63M | – | – | – | – | – | – | 1.5% | +40.3% |
| Direct selling | – | – | – | $175.83M | $199.13M | $210.45M | $209.97M | $198.47M | $211.21M | $226.15M | $219.61M | $211.93M | – | – |
| Other | – | – | $6.05M | $7.00M | $2.79M | $2.00M | $1.68M | $1.75M | $1.66M | $1.65M | $1.48M | $1.43M | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Core Nutritional | $12.82M | $18.25M | – | – | $13.31M | $16.92M | – | – | – | – | – | – | -3.7% |
| Rise | -$1.72M | -$1.77M | – | – | -$313.00K | -$721.00K | – | – | – | – | – | – | +449.5% |
| Hiya | -$31.10M | -$2.60M | $849.00K | -$636.00K | $3.72M | -$531.00K | – | – | – | – | – | – | -935.0% |
| Direct selling | – | – | – | $2.50M | $13.88M | $17.49M | $9.45M | $16.76M | $18.97M | $25.60M | – | – | – |
| Other | – | – | -$3.68M | -$639.00K | -$881.00K | -$1.29M | -$1.39M | -$1.16M | -$1.13M | -$922.00K | – | – | – |
By product or service
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asia Pacific total | $157.15M | $169.35M | $151.09M | $139.44M | $163.22M | $173.41M | $167.19M | $160.07M | $170.63M | $185.10M | $177.10M | $170.00M | 70.4% | -3.7% |
| Greater China | $114.61M | $123.33M | $100.05M | $92.57M | $113.17M | $118.75M | $112.59M | $102.26M | $115.51M | $127.62M | $115.92M | $106.61M | 51.3% | +1.3% |
| China | $105.35M | $112.51M | $89.41M | $82.62M | $102.11M | $107.69M | $101.32M | $91.28M | $105.12M | $115.75M | $104.68M | $94.67M | 47.2% | +3.2% |
| Americas and Europe | $66.13M | $80.87M | $75.11M | $74.23M | $72.62M | $76.13M | $46.42M | $40.15M | $42.24M | $42.70M | $43.98M | $43.36M | 29.6% | -8.9% |
| United States | $49.09M | $63.53M | $56.00M | $56.89M | $54.08M | $57.92M | $26.53M | $21.46M | $21.64M | $22.16M | $23.26M | $22.98M | 22.0% | -9.2% |
| Southeast Asia Pacific | $28.72M | $30.66M | $34.21M | $29.18M | $32.89M | $35.72M | $38.06M | $37.27M | $35.40M | $36.07M | $39.12M | $39.15M | 12.9% | -12.7% |
| North Asia | $13.81M | $15.35M | $16.83M | $17.69M | $17.17M | $18.94M | $16.54M | $20.54M | $19.71M | $21.42M | $22.07M | $24.24M | 6.2% | -19.5% |
| South Korea | – | – | $16.41M | $17.25M | – | – | $16.11M | $20.08M | $19.30M | $20.96M | $21.57M | $23.75M | – | – |
From the segment and revenue-disaggregation notes of Usana Health Sciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.